What are the latest funding news in the neurotechnology market? (July 2026)
Download our beautiful pitch about the neurotechnology market
In our neurotechnology market deck, you will find everything you need to understand the market
Neurotechnology funding stayed active through May, June and early July 2026, with 12 disclosed rounds across BCI, neuromodulation and neurodiagnostics.
The most recent deals show strong investor interest in non-invasive ultrasound brain interfaces, especially in China.
Clinical use cases also remained central, with epilepsy diagnostics, depression treatment, chronic pain, overactive bladder and vision restoration all represented.
And if you want to better understand this new industry, you can download our pitch covering the neurotechnology market.
Insights
- Ultrasound-based neurotechnology dominated the freshest activity, with Gestala, Sisen, Huachao and Sonomind all using acoustic energy for brain interfacing or neuromodulation.
- China produced three of the five newest neurotechnology deals, showing how quickly the local ultrasound BCI ecosystem is forming around early-stage capital.
- The largest disclosed round was Gestala’s $62.0M Angel+ financing, which was unusually large for an early-stage neurotechnology company.
- Most disclosed rounds focused on clinical neurotechnology, not consumer wellness, with depression, epilepsy, chronic pain, blindness and bladder dysfunction as clear target indications.
- Implantable neurotechnology remained active but more selective, with WISE, ReVision Implant and Neurosoft Bioelectronics covering electrodes, visual prostheses and cortical BCI implants.
- At least four rounds were linked to brain stimulation for psychiatric or neurological care, suggesting neuromodulation remains a core investor theme in neurotechnology funding.
- Several companies raised to move from prototypes into clinical or regulatory work, which makes this period more translational than purely research-driven.
- Disclosed funding exceeded $220M across the 12 rounds, even before counting the undisclosed Chinese and Ampa financings.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Summary table of the latest funding deals in the neurotechnology market as of July 2026
We define the neurotechnology market as products that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.
We include neurodevices and their enabling software such as BCIs, neuromodulation systems, and neurodiagnostic/monitoring tools, including EEG and related analytics.
We exclude pharmaceuticals, general-purpose imaging infrastructure not purpose-built for neuro, and standalone wellness or mental-health apps that do not directly capture or act on nervous-system signals.
You can also read our detailed analysis to understand how funding activity in the neurotechnology market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the neurotechnology market (we update this list every quarter) as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Gestala | 3 July 2026 | $62.0M | Angel+ | Ultrasound BCI & neuromodulation |
| Sisen Technology | 1 July 2026 | Undisclosed, at least ~$1.4M+ | Seed | Ultrasound BCI & brain drug delivery |
| Neuronostics | 30 June 2026 | ~$4.1M | New investment or Seed | EEG diagnostics & digital biomarkers |
| WISE | 17 June 2026 | $34.8M | Series D | Spinal cord stimulation & implantable electrodes |
| Huachao Shenkong / BCI-Sonics | 8 June 2026 | Undisclosed, at least ~$14.0M+ | Angel and Angel+ | AI ultrasound BCI & neuromodulation |
| Omniscient | 29 May 2026 | $27.2M | Series D | Connectomic brain mapping & neurodiagnostics |
| Sychedelic | 27 May 2026 | $3.5M | Seed | Consumer neuromodulation wearable |
| ReVision Implant | 26 May 2026 | ~$4.6M | Private financing | Cortical visual prosthesis & implantable BCI |
| Neurosoft Bioelectronics | 20 May 2026 | $7.5M | Seed | Soft cortical BCI implants |
| Ampa | 14 May 2026 | Undisclosed | Undisclosed financing | Portable TMS brain neuromodulation |
| NinaMED | 14 May 2026 | $13.75M | Company-formation financing | Peripheral neuromodulation for overactive bladder |
| Sonomind | 12 May 2026 | $23.0M to $23.5M | Series A | Focused-ultrasound neuromodulation |
All the latest funding deals during in the neurotechnology market as of July 2026
Gestala raised $62.0M in Angel+ funding in July 2026
When was it?
The deal was announced on 3 July 2026.
Who are they?
Gestala is building a non-invasive ultrasound brain-computer interface platform for brain stimulation, imaging and deep-circuit modulation.
Geographical focus?
Gestala is China-first, with Chengdu as its global headquarters and manufacturing base plus a Shanghai NeuroAI headquarters.
Why do we include them in the neurotechnology market?
Gestala belongs in ultrasound BCI and neuromodulation because its platform directly interfaces with brain activity using focused ultrasound and functional ultrasound imaging.
What is the company stage?
Gestala is early-stage, but Gestala is already moving from R&D toward prototypes, manufacturing buildout and clinical pathway definition.
How much did they raise?
Gestala raised $62.0M in this round, reported as RMB 420M.
What round is it?
The round was an Angel+ financing.
Why did they raise?
Gestala raised to accelerate ultrasound BCI development, open its Shanghai NeuroAI headquarters, and support manufacturing and clinical translation.
Sisen Technology raised seed funding in July 2026
When was it?
The seed round was reported on 1 July 2026.
Who are they?
Sisen Technology is developing AI-driven ultrasonic brain-computer interfaces for neural regulation and blood-brain-barrier-assisted drug delivery, starting with glioma.
Geographical focus?
Sisen Technology is China-focused and was founded by a team linked to Tsinghua University and ETH Zurich.
Why do we include them in the neurotechnology market?
Sisen Technology belongs in ultrasound BCI, neuromodulation and neuro-oncology enablement because its system acts directly on brain tissue.
What is the company stage?
Sisen Technology is very early-stage, founded in December 2025, with a prototype completed and animal and human trials planned.
How much did they raise?
Sisen Technology raised an undisclosed amount described as tens of millions of yuan, or at least around $1.4M.
What round is it?
The round was a Seed round.
Why did they raise?
Sisen Technology raised to build the team, develop prototypes and fund pre-clinical research around ultrasound BCI and brain drug delivery.
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Neuronostics raised about $4.1M in June 2026
When was it?
The round was announced on 30 June 2026.
Who are they?
Neuronostics makes BioEP, an EEG-based digital biomarker platform for epilepsy diagnosis and outcome prediction.
Geographical focus?
Neuronostics is Bristol-based and currently focused on UK epilepsy services, with a U.S. FDA submission planned.
Why do we include them in the neurotechnology market?
Neuronostics belongs in EEG neurodiagnostics and brain-signal analytics because BioEP directly analyzes electrical brain activity from EEG signals.
What is the company stage?
Neuronostics is at early commercial and clinical adoption stage, with NHS adoption building and U.S. regulatory work underway.
How much did they raise?
Neuronostics raised £3.0M, or about $4.1M, plus a £400K Innovate UK Investor Partnerships grant.
What round is it?
The round was described as new investment, while some startup-tracker coverage labels it Seed.
Why did they raise?
Neuronostics raised to expand BioEP across UK epilepsy services, prepare its FDA submission and extend the platform into pharma and other neurological indications.
WISE raised $34.8M in Series D funding in June 2026
When was it?
The round closed and was announced on 17 June 2026.
Who are they?
WISE develops stretchable implantable electrodes for spinal cord stimulation, neuromonitoring and BCI applications.
Geographical focus?
WISE is Italy-based and focused on European clinical adoption, with broader medtech expansion potential.
Why do we include them in the neurotechnology market?
WISE belongs in spinal neuromodulation and implantable neural interface hardware because its electrodes directly stimulate and monitor neural tissue.
What is the company stage?
WISE is late clinical to early commercial stage, especially around clinical adoption of the Heron spinal cord stimulation lead.
How much did they raise?
WISE raised €30.0M, reported as about $34.8M.
What round is it?
The round was a Series D financing.
Why did they raise?
WISE raised to advance clinical adoption of Heron and continue development of its Supersonic Technology electrode platform.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Huachao Shenkong raised angel-series funding in June 2026
When was it?
The round was reported on 8 June 2026, with some republications dated 9 June 2026.
Who are they?
Huachao Shenkong, also referred to as BCI-Sonics, is building AI-enabled ultrasound BCI technology for non-invasive and targeted brain regulation.
Geographical focus?
Huachao Shenkong is China-focused and was founded in Shanghai.
Why do we include them in the neurotechnology market?
Huachao Shenkong belongs in ultrasound BCI and non-invasive neuromodulation because its platform aims to regulate deep brain regions with ultrasound.
What is the company stage?
Huachao Shenkong is early-stage and moving from research prototypes toward clinical verification and industrialization.
How much did they raise?
Huachao Shenkong completed undisclosed angel-series financing worth hundreds of millions of RMB, or at least around $14.0M.
What round is it?
The financing included Angel and Angel+ rounds.
Why did they raise?
Huachao Shenkong raised to fund technology validation and industrial implementation of its AI and ultrasound brain-computer interface platform.
Omniscient raised $27.2M in Series D funding in May 2026
When was it?
The Series D was announced on 29 May 2026.
Who are they?
Omniscient builds Quicktome, an FDA-cleared AI brain-mapping platform for neurosurgery and neurological care.
Geographical focus?
Omniscient is linked to Sydney and San Francisco, with a commercial focus on U.S. healthcare systems and global expansion.
Why do we include them in the neurotechnology market?
Omniscient belongs in neurodiagnostics, connectomic brain mapping and clinical neurosoftware because it maps brain connectivity for neurological care.
What is the company stage?
Omniscient is growth-stage, with an FDA-cleared platform already used in clinical workflows.
How much did they raise?
Omniscient raised $27.2M in this round.
What round is it?
The round was a Series D financing.
Why did they raise?
Omniscient raised to scale Quicktome commercialization and expand into next-generation personalized brain care, including BCI, stroke and movement disorders.
In our neurotechnology market deck, we identify pain points entrepreneurs should prioritize
Sychedelic raised $3.5M in Seed funding in May 2026
When was it?
The round was announced on 27 May 2026.
Who are they?
Sychedelic makes headphones that combine tDCS neurostimulation, binaural audio and HRV biofeedback for calm, focus and sleep states.
Geographical focus?
Sychedelic is linked to New York and India, with a global consumer launch plan.
Why do we include them in the neurotechnology market?
Sychedelic belongs in consumer functional neuromodulation wearables because the hardware directly applies neurostimulation and uses biofeedback.
What is the company stage?
Sychedelic is pre-launch to early commercial stage, with product development, manufacturing and global rollout in preparation.
How much did they raise?
Sychedelic raised $3.5M in this round.
What round is it?
The round was a Seed round.
Why did they raise?
Sychedelic raised to finish product development, scale manufacturing, expand globally and build AI-enabled adaptive wellness features.
ReVision Implant raised about $4.6M in May 2026
When was it?
The round was announced on 26 May 2026.
Who are they?
ReVision Implant is building Occular, a cortical visual prosthesis that sends camera-derived information to the brain’s visual cortex.
Geographical focus?
ReVision Implant is based in Leuven, Belgium, with European clinical development and regulatory work.
Why do we include them in the neurotechnology market?
ReVision Implant belongs in implantable BCI, neuroprosthetics and visual cortex stimulation because the system directly stimulates the brain to create visual perception.
What is the company stage?
ReVision Implant is pre-human and preparing for clinical trials, with first-in-human work scheduled for Q3 2026.
How much did they raise?
ReVision Implant raised €4.0M, or about $4.6M.
What round is it?
The round was an oversubscribed private financing with no formal Series label disclosed.
Why did they raise?
ReVision Implant raised to prepare first-in-human trials, build cleanroom capabilities, expand the team and strengthen regulatory compliance.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
Neurosoft Bioelectronics raised $7.5M in Seed funding in May 2026
When was it?
The round was reported on 20 May 2026.
Who are they?
Neurosoft Bioelectronics develops soft and flexible implantable neural electrodes for long-term cortical recording and BCI applications.
Geographical focus?
Neurosoft Bioelectronics is linked to Geneva and New York, with Swiss neuroengineering roots and U.S. clinical and investor connections.
Why do we include them in the neurotechnology market?
Neurosoft Bioelectronics belongs in implantable BCI and soft neural interface hardware because its implants directly capture brain signals from cortical tissue.
What is the company stage?
Neurosoft Bioelectronics is early clinical to translational stage, advancing soft cortical BCI technology and neural-interface applications.
How much did they raise?
Neurosoft Bioelectronics raised $7.5M in this round.
What round is it?
The round was a Seed round.
Why did they raise?
Neurosoft Bioelectronics raised to advance its soft BCI platform, strengthen clinical development and expand long-term neural recording capabilities.
Ampa raised undisclosed financing in May 2026
When was it?
The financing was announced on 14 May 2026.
Who are they?
Ampa makes Ampa One, a portable transcranial magnetic stimulation system for depression treatment in clinics.
Geographical focus?
Ampa is focused on U.S. clinic rollout, with Israel commercialization following regulatory approval.
Why do we include them in the neurotechnology market?
Ampa belongs in clinical brain neuromodulation and TMS depression treatment because its device directly stimulates the brain for a validated clinical outcome.
What is the company stage?
Ampa is growth to early commercial stage, with an FDA-cleared system being rolled out to clinics.
How much did they raise?
Ampa did not disclose the exact round size, but public reporting says total funding now exceeds $25.0M.
What round is it?
The round was an undisclosed financing.
Why did they raise?
Ampa raised to accelerate rollout of its portable neuromodulation system, meet U.S. demand and launch commercial operations in Israel.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
NinaMED raised $13.75M in launch financing in May 2026
When was it?
The financing was announced on 14 May 2026.
Who are they?
NinaMED is developing the NiNA System, a non-invasive at-home wearable neuromodulation therapy for overactive bladder.
Geographical focus?
NinaMED is Melbourne-based and holds global commercialization rights to the NiNA System.
Why do we include them in the neurotechnology market?
NinaMED belongs in peripheral neuromodulation and urology neurodevices because the system targets nerve activity to treat bladder symptoms.
What is the company stage?
NinaMED is newly formed and is in clinical-development and regulatory-preparation stage.
How much did they raise?
NinaMED raised $13.75M in this financing.
What round is it?
The round was a company-formation and launch financing.
Why did they raise?
NinaMED raised to license and advance NiNA, accelerate clinical development, support regulatory work and prepare global commercialization.
Sonomind raised about $23.5M in Series A funding in May 2026
When was it?
The round was announced on 12 May 2026.
Who are they?
Sonomind develops a non-invasive focused-ultrasound neuromodulation system for treatment-resistant depression.
Geographical focus?
Sonomind is France-based, with clinical development aimed at European and broader regulated markets.
Why do we include them in the neurotechnology market?
Sonomind belongs in focused-ultrasound neuromodulation and psychiatric neurodevices because its device directly stimulates brain regions using acoustic energy.
What is the company stage?
Sonomind is clinical-development stage, preparing larger sham-controlled trials and industrial development, with market authorization targeted around 2029.
How much did they raise?
Sonomind raised €20.0M, reported as about $23.0M to $23.5M.
What round is it?
The round was a Series A financing.
Why did they raise?
Sonomind raised to run larger clinical trials, industrialize the platform and test non-invasive deep brain targeting for resistant depression.
Related blog posts
- How strong is fundraising in the neurotechnology market right now?
- The most recent news in the neurotechnology market
- How large is the neurotechnology market in reality?
- The evolution of funding activity in the neurotechnology market
- The main fundraising trends in the neurotechnology market
- All funding deals in the neurotechnology market
- Which companies have raised the most funding in the neurotechnology market?
- Which companies are the most valued in the neurotechnology market?
- A complete list of business models in the neurotechnology market
